

Special Issue

10th Anniversary of Biomedicines—Biomarkers in Pain

Message from the Guest Editors

During the last decade, biomarkers related to chronic pain have been investigated. The discovery of such markers could not only be used to improve diagnoses and prognostication of patients with chronic pain but could also support those who file an insurance claim after an injury. Biomarkers of pain could also be used to distinguish different causes of pain, allowing for improved selection of treatments. Such markers could also provide pharmaceutical companies with a tool for evaluating pain relief effects in clinical trials. The focus of this Special Issue of *Biomedicines* is on the value of biomarkers of pain in a broad perspective. Biomarkers of pain may be used to identify and quantify pain of various origin in order to facilitate adequate therapeutic interventions. Extensive prescription of analgesics, especially opioids, is associated with overdose deaths. Although pain is a subjective experience, the use of determinants of pain as an end point in clinical trials may help to predict safety as well as the analgesic efficacy of new drugs.

Guest Editors

Dr. Mats B. Eriksson

Department of Surgical Sciences, Anaesthesiology and Intensive Care Medicine, Uppsala University, 751 85 Uppsala, Sweden

Prof. Dr. Anders O. Larsson

Department of Medical Sciences, Clinical Chemistry, Uppsala University, 751 85 Uppsala, Sweden

Deadline for manuscript submissions

closed (15 June 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/112880

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).